Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase 3 1

Status

Completed 5Recruiting 2Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Myasthenia Gravis 3Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Hizentra × Clear all
NCT04728425 2025-04-27

MG_SCIG

University Health Network, Toronto

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT02774239 2023-02-21

SCIG-MG

University of Alberta

Phase 3 Completed
26 enrolled

Myasthenia Gravis

NCT02100969 2021-06-02

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

University of Kansas Medical Center

Phase 2 Completed
23 enrolled 18 charts

Myasthenia Gravis

NCT03211065 2021-04-19

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03730129 2020-08-26

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡